Longevity Peptide Stacks: How the Anti-Aging Compounds Work Together

Longevity peptides are a set of separate research compounds that each act on a different mechanism of ageing: Epitalon on telomeres, NAD+ on the cellular fuel pool, MOTS-c on the mitochondrial signal, SS-31 on mitochondrial structure, and GHK-Cu on gene expression and connective tissue. The point is combining complementary mechanisms, not finding one hero compound.

"What is the best peptide for longevity?" is the wrong question, and it is the one almost everyone starts with. There is no single answer because ageing is not one process. Telomeres (the protective caps on the ends of DNA that get shorter every time a cell divides) shortening, the NAD+ pool (NAD+ being a coenzyme cells need to turn food into usable energy) draining, mitochondria (the tiny power plants inside every cell) losing signal and structure, skin and connective tissue thinning out, these are different problems with different mechanisms. A compound that acts on one of them does nothing for the others.

So the useful question is not "which one," it is "how do they fit together." That is what this guide is about. We will not write a monograph on each compound, the deep-dives do that. We will map each one to the lever it actually pulls, then show the single most important principle in building a longevity stack: you lay down fuel and protection before you push the system, or you make things worse.

Which longevity peptide does what?

Each longevity peptide owns a different lever of ageing, so they complement rather than compete: Epitalon for telomeres, NAD+ for the cellular fuel pool, MOTS-c for the mitochondrial signal, SS-31 for mitochondrial structure, and GHK-Cu for gene expression and connective tissue. Think of "anti-aging" as a small set of separate dials. Here is who turns which.

• Telomeres: Epitalon. Epitalon (the AEDG tetrapeptide, meaning a tiny chain of four amino acids) is the canonical "telomere peptide." In cell culture it upregulates telomerase (hTERT), the enzyme that rebuilds those telomere caps, and lengthens telomeres in human cell cultures, first reported by Khavinson in 2003 (Khavinson 2003) and independently replicated by a Brunel University London group in 2025 (Al-Dulaimi 2025). One study in elderly subjects reported restoration of the night-time melatonin rhythm that fades with age (Korkushko 2004). Its honest evidence ceiling matters: telomere lengthening is demonstrated in vitro (in cells in a dish, not in a living person), not in a controlled human telomere-length study, and the lifespan data is from mice and flies (around +12 to 13% in SHR mice, Anisimov 2003), not people. More in the Epitalon deep-dive.
• The cellular fuel pool: NAD+. NAD+ is the coenzyme mitochondria run their core reactions on, and it measurably declines with age (Camacho-Pereira 2016). It is the "fuel" of the stack, the cofactor (a helper molecule a reaction can't run without) that has to be present for the other levers to do anything useful. Honest caveat up front: nearly all the good human data is on the oral precursors (NR, NMN), the raw materials the body converts into NAD+, not on injected NAD+ itself, and even the precursor data is mixed.
• The mitochondrial signal and biogenesis: MOTS-c. (Biogenesis just means making new mitochondria.) MOTS-c is a mitochondrial-derived peptide (a short protein mitochondria make themselves) that acts like an exercise signal. In animal and cell models it activates AMPK (the cell's master fuel sensor), with reported effects on insulin sensitivity (how efficiently cells respond to insulin and take up glucose from the blood) and fat oxidation (the burning of fat for energy), and drives PGC-1-alpha, the master switch for building new mitochondria (Lee 2015; Reynolds 2021). It is the accelerator. Crucially, it is a signal to spend energy, not a supply of it. Full detail in the MOTS-c deep-dive.
• Mitochondrial structural protection: SS-31. SS-31 (elamipretide) binds cardiolipin, the structural lipid of the inner mitochondrial membrane, and in preclinical models supports the membrane and its electron-transport machinery (the chain of proteins that turns fuel into ATP, the cell's energy currency) under load (Mitchell 2020; Szeto 2014). It does not signal anything. It is the structural-protection lever. It is also the only compound here with a Western regulatory approval, an FDA accelerated approval in 2025 (a fast-track US approval pathway for drugs that address serious conditions with few other options) for the rare disease Barth syndrome (a rare inherited disorder that weakens the heart and muscles), though that approval rests on a knee-strength signal in 12 patients and tells you little about healthy-adult longevity.
• Gene expression and connective repair: GHK-Cu. GHK-Cu is a copper tripeptide (a tiny three-amino-acid chain carrying a copper atom) that, in published reviews, shifts a broad set of genes toward a "younger," more regenerative expression pattern and stimulates collagen synthesis, the protein that gives skin and connective tissue its structure (Maquart 1988; Pickart & Margolina 2018). In a longevity context it is the skin, hair and connective-tissue lever, with the strongest evidence base of the group on the dermatological side. See GHK-Cu.

These do not compete. They sit on different dials. That is exactly why they get stacked, and exactly why stacking them carelessly is a mistake.

Why does the foundation have to come before the accelerator?

Because the most common way a longevity stack goes wrong is pushing the system before it has been fuelled and protected. If you take one thing from this guide, take this: the foundation compounds (NAD+ as fuel, SS-31 as protection) go down first, and the MOTS-c accelerator goes on top of them, not the other way round.

The clearest worked example is the MOTS-c paradox, and it is worth understanding because it generalises to the whole stack. MOTS-c does not supply energy to a cell. Its mechanism signals cells to produce and spend more of it, by switching on AMPK. In a well-supplied cell that signalling is the exercise-mimetic effect the research describes. In a depleted one, the same signal drives a fragile system harder, and the reported real-world pattern is fatigue, brain fog or a crash, often a couple of weeks into a cycle. This is not a bad batch. It is the compound doing its job to a system that was not set up for it.

Two things drive that crash, and each maps to a foundation compound:

1. The signal burns through fuel and substrate. The folate-AMPK pathway MOTS-c works through was reported to deplete folate and methionine (two B-vitamin-linked building blocks cells run on) and raise homocysteine, a byproduct that is a problem when it builds up, within hours in the original mechanistic work (Lee 2015). And ramping up mitochondrial work needs the NAD+ coenzyme present to actually run the reactions. NAD+ is the tank. Methylfolate and B12 cover what MOTS-c specifically drains.
2. Pushing an unprotected engine. Driving more work through mitochondria whose membranes are already compromised is, mechanistically, a path to inefficiency and oxidative stress rather than usable energy. SS-31 is the structural-protection lever under that load.

So the sequence is not arbitrary. NAD+ is the fuel, SS-31 is the protection, and only on top of those does the MOTS-c accelerator have something to work with. The community framing is the car analogy: MOTS-c is like flooring the accelerator, which makes sense if there is fuel in the tank and the engine is sound, and is a way to burn the engine out if there is not.

The honest framing on the foundation pieces themselves: this logic is mechanistically clean and widely used, but it has not been validated as a stack in any trial. The NAD+ side in particular comes with a real asymmetry, which is that injected NAD+ has only a single small human pharmacokinetic study (one that tracks how much of a dose actually reaches the blood and how fast) behind it (Grant 2019, in which plasma NAD+ did not rise for the first two hours of infusion), while the stronger human evidence sits with the oral precursors. None of that breaks the "fuel first" logic. It just means the foundation is sensible groundwork, not proven medicine.

How do the longevity peptides combine into a stack?

A longevity stack combines four jobs in order: signal, fuel, protection, and then the longer-horizon levers layered alongside. Once you stop thinking "which peptide" and start thinking "which levers," the structure builds itself.

The documented community "mito stack" is the worked example:

• MOTS-c is the signal that drives mitochondrial work and biogenesis.
• NAD+ is the fuel that lets the cell deliver on that demand.
• SS-31 is the structural protection that keeps the engine intact under the extra load.
• Methylfolate plus B12 cover the cofactor and substrate that MOTS-c depletes, which is standard community advice and especially relevant for people with MTHFR gene variants, a common inherited quirk that makes it harder to process folate.

This is a mechanistically coherent, community-built protocol, not a trial-proven regimen, and that distinction is the whole honesty of the thing. The three peptides target three different axes in the preclinical literature (Mitchell 2020 for the structure; Lee 2015 and Reynolds 2021 for the signal; Camacho-Pereira 2016 for the fuel rationale), but no controlled human trial has tested them together. Treat it as a smart pairing of complementary mechanisms, which is the core idea behind peptide stacking, rather than as a validated stack.

Where Epitalon and GHK-Cu fit alongside. The mito stack handles the energy axis. The other two longevity levers sit beside it rather than inside it:

• Epitalon runs on a different clock entirely. It is course-based, not continuous, typically a 10 to 20 day course once or twice a year (the canonical Khavinson pattern), targeting telomeres and the pineal/circadian axis, meaning the brain's melatonin gland and your daily sleep-wake clock, that the mito compounds do not touch. It does not need to be "on" while you run the mito stack. It is an annual or semi-annual tune-up layered over the top.
• GHK-Cu addresses the visible, connective side, skin, hair, collagen, that none of the mito compounds reach. It pairs naturally with the rest because it works on a separate mechanism, and it carries the strongest dermatological evidence of the group.

The shape of a full longevity approach, then, is a continuous-but-cycled energy foundation (NAD+ and SS-31), an accelerator added onto that foundation (MOTS-c), a periodic telomere/circadian course (Epitalon), and a connective-tissue layer (GHK-Cu) running to its own schedule.

What are the common mistakes when stacking longevity peptides?

The common mistakes are pushing MOTS-c on a depleted system, over-stacking, doubling up on overlapping mechanisms, and ignoring compound-specific cautions. Most of them come from the same instinct, that more must be better. It is not.

• Do not push MOTS-c on a depleted system. This is the headline mistake and the reason the crash happens. If you are already run-down and unwilling to lay down NAD+, the folate cofactors and SS-31 first, MOTS-c is the wrong place to start. Build the foundation, then add the signal.
• Do not over-stack. Running five compounds at once because each one "does something for longevity" is not a strategy, it is noise. You cannot tell what is working, what is causing a side effect, or what to adjust. Add one lever at a time, give it a few weeks, and keep what earns its place.
• Do not stack overlapping mechanisms. Pairing complementary mechanisms is the point. Stacking two compounds that pull the same lever just doubles the cost and the side-effect load for no extra benefit. The mito stack works because signal, fuel and protection are three different jobs, not three versions of the same one.
• Mind the specific cautions. MOTS-c is on the WADA prohibited list, so it is off-limits for tested athletes, full stop, and the same non-approved-substance logic plausibly reaches the others for athletes too (WADA Prohibited List 2026). Injected NAD+ should only ever come from properly compounded, sterile product, never gray-market material, because of real endotoxin (bacterial contamination that triggers a strong immune reaction) and reaction risk. And Epitalon's mechanism is telomerase activation, the same machinery cancer cells exploit, so anyone with active or recent cancer or a strong family history should treat that as an unresolved flag rather than a settled non-issue.

One thing about route: research handling here is subcutaneous (a small injection into the fat just under the skin), not intravenous (straight into a vein). NAD+ in particular is marketed heavily as a premium IV drip, and the clinical and addiction-clinic literature uses the IV route, but that is mentioned here only as background, not as something to do at home. The acute IV experience reported in the literature is rough (in one 2026 study every NAD+ IV client reported moderate-to-severe cramping, nausea and chest pressure during infusion, Reyna 2026), and home IV is not a route we support. Subcutaneous dosing is the practical path, and BAC (bacteriostatic, meaning it contains a preservative that stops bacteria from growing) water is the only correct diluent.

How should you sequence and cycle a longevity stack?

Start with the foundation, layer the signal on top, then add the periodic and visible levers, and cycle in blocks rather than running everything indefinitely. The build order follows directly from the foundation-first principle.

1. Start with the foundation. Lay down the fuel and the protection before anything else: NAD+ and SS-31, plus the methylfolate/B12 cofactors. Give it a couple of weeks. This is the part that determines whether the accelerator helps or hurts.
2. Layer in the signal. Once the foundation is in place, add MOTS-c. It clears the blood quickly but its signalling effect on cellular energy is reported to outlast the compound in circulation, so it does not need daily dosing, which is why community patterns cluster at a few times a week rather than daily.
3. Add the periodic and the visible. Epitalon comes in as a separate, course-based block once or twice a year rather than a continuous add-on. GHK-Cu runs on its own connective-tissue schedule, layered in when skin, hair and collagen are the goal.

On cycling: the mito-stack peptides are typically run in blocks, commonly 8 to 12 weeks on followed by a break, rather than continuously and forever. Epitalon is explicitly course-based, a short annual or semi-annual run, not a daily habit. The general principle, that you cycle these rather than running them flat-out indefinitely, is partly caution (long-term human safety data is thin across the board) and partly the simple fact that signalling compounds work better with breaks than without.

If you are new to mixing and dosing any of this, how to reconstitute and dose covers the practical side, BAC water, swirling not shaking, storage and so on. A note worth flagging: NAD+ is unusually light-sensitive and degrades in the wrong conditions, so it is one of the few compounds where handling genuinely affects whether you are injecting anything active.

Do longevity peptides actually work?

The mechanisms are real and in several cases well-studied, but the human outcome data is thin to absent, so no longevity peptide is proven to extend human lifespan. Longevity is the single most hype-prone corner of the peptide world, and it is worth being blunt about where the evidence actually sits, because the marketing rarely is.

The mechanisms are real and, in several cases, well-studied. AMPK activation and mitochondrial biogenesis from MOTS-c, cardiolipin binding from SS-31, NAD+'s central metabolic role, telomerase upregulation from Epitalon, gene-expression shifts from GHK-Cu, all of that has genuine preclinical and biochemical backing. The human outcome data is thin. There is no completed human efficacy trial of native MOTS-c. Injected NAD+ rests on one small pharmacokinetic study. SS-31's anti-ageing case is built on aged-mouse data, not human longevity trials. Epitalon's telomere effect is shown in cells, not in a controlled human telomere study, and its lifespan numbers are from mice and flies.

So the honest line is this: none of these compounds is proven to extend human lifespan, and anyone who tells you otherwise is selling. What you have instead is a set of coherent, complementary mechanisms with encouraging early signals, used widely by an informed community, and best run as a thoughtfully-sequenced stack rather than a pile of hopeful vials. That is a perfectly good reason to be interested. It is not a reason to believe more than the data supports.

On where these compounds come from, since the industry tends to stay quiet about it: research peptides are largely China-sourced, and proper per-batch third-party testing is thin across the whole sector. Primogen does not run its own testing yet, that own-batch Janoshik testing is on the roadmap as we scale; for now we rely on vetted suppliers and their reference COAs (Certificates of Analysis, the lab reports that confirm a product's purity and identity), and we are upfront about exactly that.

Humanin and Thymalin come up in longevity circles as further mitochondrial and thymic peptides worth watching, but they are not part of our range and not covered here.